This is the authors' abstract. We don't add key points for this paper.
Recent data have shown that anti-inflammatory responses to major injury occur immediately after trauma. Interleukin 11 (IL-11), a member of the IL-6 family, is a pleiotropic cytokine with hematopoietic, osteotrophic, and mucosa protective properties, as well as anti-inflammatory functions. IL-11 inhibits synthesis of proinflammatory cytokines, promotes a Th2-type immune response, and improves outcome after shock and sepsis in different animal models. To further investigate the role of IL-11 in the human posttraumatic immune response, we measured plasma levels of IL-11 in 216 multiple-injured patients (mean age of 40 +/- 16 [range 11-81] years; Injury Severity Score [ISS] of 31 +/- 11 [range 16-66] points; 52 women and 164 men) after injury and correlated this with demographics, clinical course, and other laboratory parameters. IL-11 was significantly elevated in polytraumatized patients compared with healthy donors (P <0.0001). The time course of IL-11 in surviving patients was an initial increase after trauma with a decrease during the first 4 weeks, whereas nonsurvivors (n=34) had a significant increase later after injury (4 weeks). IL-11 was significantly higher after abdominal trauma and in men. No correlation between systemic IL-11 and ISS or age was detected. IL-11 correlated significantly with other pro- and anti-inflammatory cytokines such as IL-18. Our data demonstrate elevated levels of systemic IL-11 after multiple injuries; however, the role of a posttraumatic increase of IL-11 has to be further analyzed. In contrast to IL-6, IL-11 in plasma does not correlate with trauma severity and seems to have no clinical relevance to outcome prediction after trauma.
No takes yet. Share an insight, caveat, or question.
Schinkel et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: